- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key HER2+ Patient Populations Evaluated in the DESTINY-Breast Program
Explore the latest advancements in HER2-positive breast cancer treatments, highlighting the promising results of DESTINY-Breast trials for improved patient outcomes.
DESTINY-Breast05 and DESTINY-Breast11 examined distinct early breast cancer populations to better understand how novel HER2-targeted therapies may improve outcomes. DESTINY-Breast05 focused on patients with high-risk, residual disease after neoadjuvant therapy, while DESTINY-Breast11 explored treatment in the preoperative setting, evaluating how these agents may enhance pathologic response. In the metastatic setting, DESTINY-Breast09 studied patients with previously untreated HER2-positive metastatic breast cancer to assess the role of antibody-drug conjugates earlier in the disease course. Examining these specific populations is essential because each group faces unique prognostic challenges and therapeutic needs.
Linking Data to Determine Risk for 30-Day Readmissions in Dementia
December 22nd 2025This study found that certain characteristics in linked electronic health record data across episodes of care can help identify patients with Alzheimer disease and related dementias at high risk of 30-day readmissions.
Read More
